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Abstract Studies of myocardial metabolism have reported
that contractile performance at a given myocardial oxygen
consumption (MVO2) can be lower when the heart is
oxidizing fatty acids rather than glucose or lactate. The
objective of this study is to assess the prognostic value of
myocardial metabolic phenotypes in identifying non-
responders among non-ischemic dilated cardiomyopathy
(NIDCM) patients undergoing cardiac resynchronization
therapy (CRT). Arterial and coronary sinus plasma concen-
trations of oxygen, glucose, lactate, pyruvate, free fatty
acids (FFA), and 22 amino acids were obtained from 19
male and 2 female patients (mean age 56±16) with NIDCM
undergoing CRT. Metabolite fluxes/MVO2 and extraction
fractions were calculated. Flux balance analysis (FBA) was
performed with MetaFluxNet 1.8 on a metabolic network of
the cardiac mitochondria (189 reactions, 230 metabolites)
reconstructed from mitochondrial proteomic data (615
proteins) from human heart tissue. Non-responders based
on left ventricular ejection fraction (LVEF) demonstrated a
greater mean FFA extraction fraction (35%±17%) than
responders [18±10%, p=0.0098, area under the estimated
ROC curve (AUC) was 0.8238, S.E. 0.1115]. Calculated
adenosine triphosphate (ATP)/MVO2 using FBA correlated
with change in New York Heart Association (NYHA) class
(rho=0.63, p=0.0298; AUC=0.8381, S.E. 0.1316). Non-
responders based on both LVEF and NYHA demonstrated a
greater mean FFA uptake/MVO2 (0.115±0.112) than
responders (0.034±0.030, p=0.0171; AUC=0.8593, S.E.
0.0965). Myocardial FFA flux and calculated maximal ATP
synthesis flux using FBA may be helpful as biomarkers in
identifying non-responders among NIDCM patients under-
going CRT.
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Introduction
Cardiac resynchronization therapy (CRT) has been shown
to reduce morbidity and mortality as well as improve left
ventricular (LV) function and reverse remodeling in patients
with advanced heart failure [1–4]. However, not all patients
respond to CRT and the overall nonresponse rate is
estimated to be approximately 30% [5]. Two multicenter
trials were unable to demonstrate a prognostic value of
mechanical markers of LV function in patients undergoing
CRT [6, 7]. Cardiac imaging methods are still in an
emerging state for prediction of CRT outcome [8].
Therefore, identification of biomarkers which can predict
CRT response in heart failure patients would be of great
clinical interest.
Heart failure patients have been shown to exhibit
alterations of myocardial metabolism, which may contrib-
ute to the contractile dysfunction and to the progression of
left ventricular remodeling [9]. However, studies of
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alterations in myocardial energy metabolism in heart failure
have been contradictory [10–16]. In addition, the role of
many important metabolites in heart failure, including
lactate and glutamate, has not been well described, limiting
the application of emerging constraint based systems
biology computational methods, such as flux balance
analysis (FBA), to more completely analyze the myocardial
substrate metabolism [17]. It has been reported that
contractile performance of the heart can vary depending
on the metabolic phenotype. For instance, at a given
myocardial oxygen consumption (MVO2), contractile
performance can be lower when the heart is oxidizing fatty
acids and greater when the heart is oxidizing other
substrates such as glucose and lactate [9, 18–21]. We
hypothesized that myocardial metabolic phenotypes may
demonstrate prognostic value in heart failure patients
undergoing CRT. In this study we employed FBA, a
system-based approach, to evaluate substrate metabolism
in patients with non-ischemic dilated cardiomyopathy
(NIDCM) undergoing biventricular pacemaker-implantable
cardioverter defibrillator (BiV ICD) implantation.
Methods
Study Population
In this prospective study, 21 NIDCM patients (19 male, 2
female; mean age 56±16 years) receiving optimal, individ-
ualized therapy for heart failure underwent implantation of
a BiV ICD based on standard indications for CRT. All
patients underwent a complete cardiac evaluation, including
a history, physical exam, echocardiogram and coronary
angiography. Inclusion criteria for patients with NIDCM
were: (1) diagnosis of cardiomyopathy within 12 months of
enrollment; (2) no evidence of coronary artery disease (CAD)
as assessed by coronary angiography; (3) global moderate-to-
severe left ventricular dysfunction and dyssynchrony. All
patients were required to be clinically stable for at least one
month before completing the study protocol and fast for
more than 12 h prior to undergoing BiV ICD implantation.
Written informed consent, approved by the Human Research
Protection Program, was obtained from all study subjects.
Assessment of Myocardial Metabolism
Blood was drawn from the coronary sinus and then
immediately form the radial artery from all patients at the
time of BiV ICD implantation. Arterial and venous
concentrations of oxygen, glucose, lactate and pyruvate
were evaluated following blood drawing by the laboratory
at our institution. Furthermore, blood samples were sub-
mitted to ARUP Laboratories (Salt Lake City, UT) for
evaluation of arterial and venous plasma concentrations of
free fatty acids (FFA), glutamate, aspartate, alanine,
glutamine, arginine, citrulline, cysteine, glycine, histidine,
hydroxyproline, isoleucine, leucine, lysine, methionine,
ornithine, phenylalanine, proline, serine, taurine, threonine,
tyrosine, and valine. Arterial plasma insulin levels were
also measured for each subject.
The myocardial flux of a substrate can be expressed as
the product of the substrate arterial-coronary sinus concen-
tration difference and myocardial blood flow [22]. This
metabolic flux can be corrected for MVO2 and expressed as
the ratio of arterial-coronary sinus concentration difference
for each metabolite to the arterial-coronary sinus concen-
tration difference of oxygen, eliminating the need to
measure myocardial blood flow, as previously described
by Vanky et al. [22]. Therefore, myocardial metabolic
fluxes of all measured substrates, corrected for MVO2,
were calculated. In addition, myocardial extraction fraction
(ExtFx) for each metabolite was calculated as the ratio of
the metabolite arterial-coronary sinus concentration differ-
ence and the metabolite arterial concentration.
Flux Balance Analysis
FBA was performed on a metabolic network of the human
cardiac mitochondria (189 reactions, 230 metabolites),
which was previously reconstructed from published mito-
chondrial proteomic data (615 proteins) from human heart
tissue [23]. The metabolic fluxes acquired from patients
with NIDCM and corrected for MVO2 were used as
constraints for FBA. Optimal steady-state flux distributions
of the metabolic network were calculated with MetaFluxNet
1.8 [24]. An objective function maximizing ATP production
was chosen for the calculations and maximal ATP synthesis
flux, corrected for MVO2, was obtained.
Clinical Response Criteria
New York Heart Association (NYHA) class was assessed
prior to BiV ICD (Pre-NYHA) implantation and 8.5±
5.4 months following implantation (Post-NYHA). Patients
were classified as responders based on NYHA class
(NYHA-R) when the class decreased following implanta-
tion and as non-responders (NYHA-NR) if the class
remained unchanged or increased.
Furthermore, echocardiograms were obtained prior to
BiV ICD implantation and 6.5±4.5 months after implanta-
tion. Left ventricular ejection fraction (Pre-LVEF), left
ventricular end diastolic diameter (Pre-LVEDDM), and left
atrial diameter (Pre-LAD) were assessed on the echocardio-
grams prior to implantation and after implantation (Post-
LVEF, Post-LVEDDM, Post-LAD). Patients were classified
as responders based on LVEF (LVEF-R) when the LVEF
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increased by more than 5% and as non-responders (LVEF-
NR) if these response criteria were not satisfied.
In addition, patients who responded based on both the
NYHA class and LVEF response criteria were labeled as
complete responders (C-R). All patients who responded
based on either NHYA class or LVEF criteria were labeled
as all-responders (All-R). Finally, patients who did not
respond based on neither the NYHA class nor the LVEF
criteria were labeled as complete non-responders (C-NR).
Clinicians who performed echocardiograms and assessed
the NYHA class in all patients were blinded to the
metabolic data obtained at the time of implantation.
Statistical Analysis
Sign test was used to assess uptake or secretion of each
metabolite. Student’s t test was used to compare mean
LVEF, LVEDDM, and LAD, while Mann–Whitney U test
was used to compare NYHA class in patients before and
after BiV ICD implantation [25]. Spearman correlations
were evaluated between arterial insulin concentration,
patient age, sex, and metabolite fluxes/MVO2 as well as
metabolite extraction fractions. Nonparametric Spearman
correlations were also used to evaluate metabolic data in
NYHA-R and NYHA-NR patients [25, 26]. Student’s t test
was used to compare metabolic data in LVEF-R and LVEF-
NR patients, as well as in C-NR, C-R, and All-R patients.
Receiver-operating characteristic (ROC) curves were con-
structed using the ROCKIT 0.9B software package for
metabolic data which demonstrated statistical significance
based on Student’s t test or nonparametric Spearman
correlation [26].
Results
Demographics and Clinical Results
Patient demographics, clinical history, and type of non-
ischemic heart failure are shown in Table 1, while Table 2
shows hemodynamic parameters, LVEF, NYHA class,
LVEDDM, and LAD in non-responders and responders
to CRT. Mean Pre-LVEF was 23%±8%, which increased
to 30%±13% status post-placement of BiV ICD (p=
0.043). Furthermore, the NYHA class decreased status
post-BiV ICD implantation (p = 0.0049). Mean plasma
glucose was 116±48 (mg/dl). LVEF-NR patients were
younger than LVEF-R patients (p=0.02). C-NR patients
demonstrated lower systolic blood pressure than All-R
patients (p = 0.04).
Metabolic Results
There was net myocardial uptake of oxygen, glucose, FFA,
lactate, glutamate, aspartate (p<0.05), and net myocardial
secretion of alanine (p < 0.05). There was no statistically
Non-responders Responders
LVEF-NR C-NR LVEF-R C-R All-R
Age 46±11* 45±9 63±17* 62±22 57±17
Body weight (kg) 85.9±18.8 75.9±12.9 84.0±18.0 82.0±10.7 87.6±18.6
Height (cm) 135.1±75.9 128.6±84.8 174.9±12.3 174.0±5.9 161.6±49.2
Body mass index (kg/m2) 29.1±7.8 26.1±5.8 26.6±3.3 26.5±4.4 28.5±6.3
Current smoker 2/9 1/4 1/11 0/5 2/15
Hypercholesterolemia 4/9 1/4 7/11 3/5 9/15
ACE inhibitors 9/9 4/4 7/11 3/5 11/15
Beta-blockers 8/9 3/4 11/11 5/5 15/15
Diuretics 8/9 3/4 9/11 4/5 13/15
Digoxin 6/9 4/4 5/11 3/5 7/15
Angiotensin II blocker 1/9 1/4 4/11 2/5 4/15
Cholesterol lowering 5/9 1/4 7/11 3/5 10/15
NIDCM-type
Idiopathic 2/9 1/4 8/11 3/5 8/15
ETOH 2/9 2/4 1/11 1/5 1/15
Drug 3/9 1/4 1/11 1/5 3/15
Myocarditis 1/9 0/4 0/11 0/5 1/15
Peripartum 1/9 0/4 0/11 0/5 1/15
Familial dilated 0/9 0/4 1/11 0/5 1/15
Table 1 Patient demographics
(mean ± SD), clinical history,
and type of non-ischemic heart
failure in non-responders and
responders to CRT
Statistically significant differen-
ces between means (p<0.05) are
marked with *
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significant evidence of myocardial uptake or secretion of
pyruvate, glutamine, arginine, citrulline, cysteine, glycine,
histidine, hydroxyproline, isoleucine, leucine, lysine, me-
thionine, ornithine, phenylalanine, proline, serine, taurine,
threonine, tyrosine, or valine. Table 3 shows atrial-venous
concentration differences (AVdiff) and arterial-venous
concentration differences normalized to ventricular mass
(nVM) for all metabolites demonstrating significant myo-
cardial uptake or secretion in non-responders and respond-
ers to CRT. LVEF-NR patients demonstrated greater FFA-
AVdiff and FFA-nVM than LVEF-R patients (p=0.02 and
0.04, respectively). No significant correlation was found
between arterial insulin concentration, blood glucose, and
metabolite extraction fractions or metabolite fluxes/MVO2.
Identifications of Non-responders Based on LVEF
There were 9 patients (45%) classified as LVEF-NR and 11
patients classified as LVEF-R. Follow-up Post-LVEF was
not available in one patient. Extraction fractions for all
Non-responders Responders
LVEF-NR C-NR LVEF-R C-R All-R
HR (beats/min) 79±13 76±13 76±18 76±18 78±17
SBP (mm Hg) 108±13 98±11* 118±18 118±16 117±16*
DBP (mm Hg) 66±11 62±9 65±6 63±7 66±9
RPP (mm Hg×bt/min) 8,491±1,941 7,460±1,778 8,938±1,847 8,996±2,050 9,137±1,820
LV mass (g) 388.8±68.7 363.0±97.3 329.7±125.1 321.8±73.4 360.2±111.6
LVESD (cm) 6.1±0.5 6.0±0.3 6.3±1.3 6.5±1.0 6.3±1.1
Pre-EF (%) 25±6* 27±6 22±9* 18±11 22±8
Post-EF (%) 24±9 23±9 35±14 31±15 31±14
NYHA Pre 3.1±0.6 2.8±0.5 2.9±0.6 3.2±0.4 3.1±0.6
NYHA Post 2.4±0.7 3.0±0.8* 2.4±0.5 2.2±0.4 2.3±0.5*
Pre-LVEDDM (cm) 7.0±0.6 6.6±0.3 6.9±1.3 7.3±0.9 7.1±1.1
Post-LVEDDM (cm) 7.2±0.9 6.6±0.5 6.4±1.3 6.5±1.2 6.9±1.3
Pre-LAD (cm) 5.3±0.6 5.4±0.8 5.1±1.0 5.6±0.8 5.1±0.8
Post-LAD (cm) 5.2±0.7 5.3±0.9 5.0±0.9 5.3±0.5 5.0±0.8
Table 2 Comparison of hemo-
dynamic parameters, LVEF,
NYHA class, LVEDDM, and




ces between means (p<0.05) are
marked with *
Table 3 Arterial-venous concentration differences (AVdiff) and arterial-venous concentration differences normalized to ventricular mass (nVM)
for all metabolites demonstrating significant myocardial uptake or secretion in non-responders and responders (mean±SD)
Non-responders Responders
LVEF-NR C-NR LVEF-R C-R All-R
Alanine-AVdiff (μmol/l) −21.2±28.2 −23.5±30.4 −19.4±33.0 −33.6±26.0 −17.5±31.1
Aspartate-AVdiff (μmol/l) 2.6±8.7 −2.5±8.5 0.7±2.1 −0.2±0.4 2.7±5.1
FFA-AVdiff (μmol/l) 315.6±232.3* 335.0±151.5 123.6±86.5* 138.0±106.2 185.3±194.8
Glucose-AVdiff (μmol/l) 238.3±481.1 247.5±222.3 315.0±1212.5 286.0±284.2 289.7±1083.3
Glutamate-AVdiff (μmol/l) 50.3±33.2 33.8±43.6 29.1±21.8 27.4±27.9 41.5±25.9
Lactate-AVdiff (μmol/l) 325.6±347.8 50.0±92.6 222.0±287.4 31.1±79.8 336.7±331.5
O2-AVdiff (μmol/l) 5,107±1,787 4,126±2,184 4,478±888 4,256±895 4,962±1,154
Alanine-nVM (μmol/l/g) −0.063±0.080 −0.079±0.095 −0.049±0.136 −0.134±0.119 −0.042±0.116
Aspartate-nVM (μmol/l/g) 0.002±0.029 −0.014±0.036 0.001±0.006 −0.001±0.002 0.006±0.013
FFA-nVM (μmol/l/g) 0.864±0.662* 1.017±0.642 0.343±0.259* 0.369±0.298 0.504±0.507
Glucose-nVM (μmol/l/g) 0.651±1.143 0.735±0.621 −0.431±6.348 1.138±1.427 −0.138±5.276
Glutamate-nVM (μmol/l/g) 0.120±0.084 0.074±0.105 0.099±0.094 0.120±0.135 0.125±0.084
Lactate-nVM (μmol/l/g) 0.787±0.879 0.086±0.303 0.944±1.423 0.111±0.271 1.143±1.243
O2-nVM (μmol/l/g) 13.54±4.93 12.41±7.31 14.22±4.04 12.94±3.38 14.40±3.58
Statistically significant differences between means (p<0.05) are marked with *
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metabolites demonstrating significant myocardial uptake or
secretion in responder and non-responder patients based on
LVEF are compared in Table 4. LVEF-NR patients
demonstrated a greater mean FFA-ExtFx (35%±17%) than
LVEF-R patients (mean FFA-ExtFx=18%±10%, p=
0.0098), as shown on box plots in Fig. 1. The area under
the estimated ROC curve (AUC) for FFA-ExtFx was
0.8238 (S.E. 0.1115) in the identification of LVEF-NR
patients.
Identification of Non-responders Based on NYHA Class
There were 9 patients classified as NYHA-NR and 11 patients
classified as NYHA-R. Follow-up post-NYHA class was not
available in one patient. There was no significant correlation
between the change in LVEF and the change in NYHA class
in our patient population (Spearman’s rho=0.029, p=0.908).
Measured flux data for glucose/MVO2, lactate/MVO2, FFA/
MVO2, and glutamate/MVO2 were fully concordant with
the FBA of the human cardiac mitochondria metabolic
network in 12 patients. Therefore, for these patients, the flux
data could be entered into MetaFluxNet 1.8 as exact
constraints rather than maximal/minimal flux bounds. Max-
imal ATP synthesis flux, corrected for MVO2 (ATP/MVO2),
was calculated. For the remaining patients, measured flux
data were concordant with the FBA of the human cardiac
mitochondria metabolic network only if entered into Meta-
FluxNet 1.8 as maximal/minimal flux bounds and were not
used in subsequent analyses. Calculated ATP/MVO2 using
FBA correlated with change in NYHA class (Spearman’s
rho=0.63, p=0.0298). The AUC for ATP/MV02 was 0.8381
(S.E. 0.1316) for the identification of NYHA-NR patients.
No significant correlation was found between change in
NYHA class and other metabolite fluxes/MVO2 or extrac-
tion fractions.
Identification of Complete Non-responders
There were 4 patients classified as C-NR (non-responders
based on both LVEF and NYHA criteria), 15 patients
classified as All-R (responders based on either LVEF or
NYHA criteria or both), and 5 as C-R patients (responders
based on both LVEF and NYHA criteria). C-NR patients
demonstrated a greater mean FFA-ExtFx (39%±12%) than
C-R patients (mean FFA-ExtFx=14%±9%, p=0.0086), as
shown on box plots in Fig. 1 and Table 4. Metabolite
fluxes/MVO2 for all metabolites demonstrating signifi-
cant myocardial uptake or secretion in responders and
non-responders to CRT are also compared in Table 4. C-
NR patients demonstrated a greater mean FFA/MVO2
(0.115±0.112) than All-R patients (mean FFA/02=0.034±
0.030, p=0.0171), as shown in Fig. 1 and Table 4. The
AUC for FFA/MVO2 was 0.8593 (S.E. 0.0965) and
0.8141 (S.E. 0.1159) for FFA-ExtFx in the identification
of C-NR patients.
Discussion
In our study, 21% of patients with NIDCM who underwent
CRT neither improved their NYHA class nor their LVEF
during the mean follow-up period of more than 6 months.
Table 4 Metabolite extraction fractions (ExtFx) and metabolite fluxes corrected for MVO2 in non-responders and responders (mean ± SD)
Non-Responders Responders
LVEF-NR C-NR LVEF-R C-R All-R
Alanine-ExtFx (%) −9±10 −13±13 −8±13 −15±13 −7±11
Aspartate-ExtFx (%) −1±97 −48±136 7±21 −2±4 17±28
FFA-ExtFx (%) 35±17* 39±12** 18±10* 14±9** 22±16
Glucose-ExtFx (%) 4±7 5±4 4±19 5±5 4±17
Glutamate-ExtFx (%) 41±27 27±36 32±20 22±16 40±20
Lactate-ExtFx (%) 21±19 5±10 18±18 4±10 24±18
O2-ExtFx (%) 58±18 49±24 57±12 50±12 59±12
ATP/MVO2 4.72±0.34 4.93±0.15 4.94±0.11 4.90±0.08 4.78±0.31
Alanine/MVO2 −0.006±0.008 −0.010±0.010 −0.005±0.008 −0.008±0.006 −0.004±0.007
Aspartate/MVO2 0.001±0.002 0.000±0.002 0.000±0.000 0.000±0.000 0.000±0.001
FFA/MVO2 0.077±0.084 0.115±0.112*** 0.027±0.017 0.033±0.022 0.034±0.030***
Glucose/MVO2 0.050±0.079 0.055±0.027 0.040±0.312 0.069±0.068 0.040±0.270
Glutamate/MVO2 0.012±0.015 0.014±0.023 0.007±0.005 0.007±0.007 0.008±0.005
Lactate/MVO2 0.063±0.069 0.014±0.022 0.049±0.065 0.006±0.020 0.068±0.071
Statistically significant differences between means (p<0.05) are marked with *, **, and ***
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These patients demonstrated greater myocardial uptake of
FFA at the time of implantation than the 79% of patients
who responded to CRT (Box plot c, Fig. 1). These findings
suggested that myocardial FFA uptake flux may be a useful
biomarker for identifying complete non-responders among
non-ischemic heart failure patients undergoing CRT. The
possibility of finding such a biomarker for complete non-
responders is intriguing, particularly, since we did not
observe a significant correlation between the change in
LVEF and change in NYHA class in our patient population.
Therefore, ROC curves were constructed and the areas
under the ROC curves were estimated to be 0.8593 for
FFA/MVO2 data and 0.8141 for FFA-ExtFx in the
identification of C-NR patients. If we were to use FFA-
ExtFx as a biomarker for identifying C-NR patients, we
could potentially avoid the error of excluding complete
responders (C-R) from undergoing treatment, since we
there was no overlap in FFA-ExtFx between complete non-
responder and complete responder groups (Box plot b,
Fig. 1). Our study further demonstrated that patients who
did not responded to BiV ICD implantation based strictly
on the LVEF criteria also exhibited markedly greater
myocardial FFA uptake rate than LVEF responders (Box
plot a, Fig. 1). If we were to use FFA-ExtFx as a biomarker
to identify LVEF-NR, we would prefer to set the cutoff
point to a high specificity, such as 95%, and the
corresponding sensitivity would be estimated at 70%.
It has been established that myocardial metabolism is
altered in patients with heart failure (HF). However, studies
of alterations in myocardial energy metabolism that may
occur in heart failure have yielded conflicting results.
Several studies, including a study by Taylor et al., have
demonstrated increased myocardial FFA metabolism and
decreased myocardial glucose metabolism in patients with
HF [10–12]. On the other hand, some animal studies and
human studies, including a study by Dávila-Román et al.,
have suggested that substrate metabolism may revert to a
fetal-like state with reduced FFA utilization and enhanced
glucose uptake in the failing myocyte [13–16]. Dávila-
Román et al. [16] compared myocardial FFA utilization
(MFAU) and MVO2 in patients with Idiopathic Dilated
Cardiomyopathy (IDCM) and normal controls. Mean
MFAU in IDCM subjects (134±44 nmol/g/min) was lower
than MFAU in normal controls (213±49 nmol/g/min).
Mean MVO2 in IDCM patients (4,935±770 nmol/g/min)
was unchanged when compared with mean MVO2 in
normal controls (4,934±830 nmol/g/min). Therefore the
MFAU/MVO2 in normal controls could be approximated as
213/4,934=0.0432 and in IDCM as 134/4,935=0.0272 for
the Dávila-Román et al. study. In our study, All-R patients
demonstrated mean FFA/MVO2 (0.0343±0.0300) similar
to the mean MFAU/MVO2 (of approximately 0.0272)
reported in patients with IDCM in the study by Dávila-
Román et al. [16]. C-NR patients in our study, on the other
hand, demonstrated a hyper-elevated mean FFA/MVO2
(0.1150±0.1118) that was greater than mean MFAU/MVO2
reported in IDCM patients (approximately 0.0272) by
Dávila-Román et al. [16, 27], as well as in healthy older
males (0.035±0.001) and healthy younger males (0.051±
0.002). Therefore, the markedly increased myocardial FFA
flux in our C-NR patients may be more closely related to
findings reported in the study by Taylor et al. [11] who
reported increased myocardial FFA metabolism in patients
with HF. These authors concluded that myocardial fatty
acid uptake rates in heart failure are higher than expected
for the normal heart and that this shift of myocardial
substrate use may be an indication of impaired energy
efficiency in the failing heart, which could also be the case
for our complete non-responder patient group [11].
It has been reported that myocardial contractile
performance at a given MVO2 is lower when the heart
is oxidizing fatty acids than when the heart is oxidizing
other substrates such as glucose and lactate [9, 18–21]. A
decrease in cardiac efficiency has been observed in healthy
humans and experimental animals with elevated FFA
during ischemia [19, 28–30]. Increasing myocardial fatty
acid uptake in dogs with an infusion of triglycerides
resulted in an increase in MVO2 without improvement in
mechanical power [21, 31]. Furthermore, treatment with a
partial fatty acid oxidation inhibitor ranolazine improved
mechanical efficiency as well as left ventricular function
in dogs with heart failure [32, 33]. In our study, complete
non-responders demonstrated excessively elevated myo-
cardial FFA uptake, which may have impaired mechanical
Fig. 1 Box plots comparing mean free fatty acid extraction fraction
(FFA-ExtFx) for responders based on LVEF (LVEF-R) and non-
responders (LVEF-NR; a, p=0.0098) as well as complete responders
(C-R) and complete non-responders (C-NR; b, p = 0.0086). Box plots
comparing mean FFA/MVO2 for all responders (All-R) and complete
non-responders (C-NR; c, p = 0.0171)
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efficiency of the myocardium with high fatty acid
oxidation, resulting in a poor response to CRT.
In the FBA modeling platform, the possible ranges of all
metabolic fluxes are first constrained by the stoichiometry
of the reactions in the network due to conservation of mass
balance and thermodynamics. Subsequently, additional
constraints of measured metabolic fluxes are applied and a
selected objective function flux that is of interest to the
investigator can be calculated using linear programming.
However, the application of too few measured fluxes as
constraints will result in an unbounded solution space for
the objective function flux. The abundance of myocardial
metabolic data collected for NIDCM patients in this study
allowed us to perform an analysis of the human cardiac
mitochondria metabolic network using FBA. We hypothe-
sized that failing myocytes would strive to maximize ATP
production based on available substrates, and therefore, an
objective function maximizing the ATP synthesis flux
relative to available oxygen was chosen for the analysis of
the human cardiac mitochondria metabolic network. In our
study, patients with high ATP/MVO2 values were less
likely to respond to CRT based on NYHA criteria. These
findings may indicate that NYHA-NR patients may need to
generate a greater amount of ATP relative to available
oxygen to maintain basal cardiac workload, which may
represent an already fully compensated metabolic state with
no potential for improvement with resynchronization
therapy [34].
One of the limitations of this study is that myocardial
metabolite fluxes could only be expressed as values
corrected for MVO2, or approximated by substrate extrac-
tion fractions, since myocardial blood flow measurements
were not performed. Nevertheless, comparison of myocar-
dial fluxes corrected for MVO2 may be more clinically
relevant than evaluation of absolute fluxes. According to
Kates et al. [35], correction of substrate fluxes with MVO2
may help to normalize the flux data for differences in
workload between subjects of different ages, since the
systolic and diastolic blood pressures are typically higher in
the older subjects compared with younger subjects. Another
limitation of the study concerns the fact that only NIDCM
patients were enrolled in the protocol and the sample size
was small. Although the patient population enrolled in the
study was homogenous, it is not known if the results of this
study can be generalized to all heart failure patients
undergoing CRT. Nevertheless, we wished to avoid the
confounding effects that CAD and ischemic cardiomyopa-
thy can have on the segmental and global measurements of
myocardial uptake of glucose, FFA, lactate, and other
metabolites [36]. Finally, since this study did not involve
radiolabeling of FFA, we were unable to differentiate
between the handling of aqueous soluble and of lipid FFA
fractions by myocardial tissue [37].
The results of our study indicate that myocardial FFA
uptake flux might serve as a useful biomarker for identifying
non-responders among NIDCM patients undergoing BiV ICD
implantation. However, the process of data collection to
obtain FFA-ExtFx is invasive, and the data becomes available
only after the decision to implant BiV ICD device has been
made. Therefore, a noninvasive test would be desirable, which
could be carried out prior to the decision process of device
implantation. Single photon emission computed tomography
(SPECT) with 123I-15-(ρ-idophenyl)-3-methyl-pentadeca-
noic acid (BMIPP) offers the possibility of noninvasive
semiquantitative assessment of regional FFA myocardial
metabolism, which can be carried out on conventional nuclear
medicine cameras that are widely available at diagnostic
imaging facilities. Alternatively, positron emission tomogra-
phy (PET) with C-11 palmitate could be utilized to assess
regional myocardial metabolism quantitatively. Therefore,
based on our invasive measurements of myocardial metabo-
lism, we believe that a noninvasive prospective SPECT or
PET imaging study is warranted, enrolling a large number of
heart failure patients who are candidates for CRT.
Our results indicate that myocardial FFA flux may be
helpful as a biomarker in identifying non-responders in
NIDCM patients undergoing CRT. These findings further
suggest that noninvasive imaging of myocardial FFA
uptake in NIDCM patients prior to CRT with technologies,
such as PET or SPECT, may be helpful in the selection
process of potential non-responders and should be investi-
gated prospectively in a large patient population. Further-
more, analysis of the myocardial metabolic network using a
systems biology approach, such as FBA, may provide
unique and clinically useful prognostic information in
patients with NIDCM undergoing therapy.
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